Journal of Pharmacovigilance

Claudio Cantatrione

Publications

• Research Article
  Non-Ergot Dopamine Agonists don't Increase the Risk of Heart Failure in Parkinson's disease Patients. A Meta-Analysis of Randomized Controlled Trials
  Author(s): Renato De Vecchis, Claudio Cantatrione, Damiana Mazzei and Cesare BaldiRenato De Vecchis, Claudio Cantatrione, Damiana Mazzei and Cesare Baldi
  
  Background: In recent years, some observational studies suggested that pramipexole, a non-ergot dopamine agonist (DA) used for the treatment of Parkinson’s disease (PD), may increase the risk of heart failure (HF). However, the limitations inherent in observational studies made it difficult to determine whether the excess of incident HF was related to the drug or to other determinants. Thus, some concerns remained regarding the increased putative HF risk associated with non-ergot DAs as a class or individually. Method: In our meta-analysis, primary endpoint was the risk of incident HF in patients with PD treated with non-ergot DAs compared to those treated with monotherapy with levodopa. Secondary outcome measures were all-cause mortality and cardiovascular events. For these purposes, only randomized controlled trials .. View More»
  DOI: 10.4172/2329-6887.1000197

  Abstract PDF